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Abstract
Introduction: Extracellular matrix (ECM) degradation leads to malfunction of the cartilage in osteoarthritis (OA).
Inflammatory cytokine interleukin-1 beta (IL-1b) functions in ECM degradation and prevents ECM synthesis by
down-regulating the key transcription factor, Sox9, and consequently inhibiting ECM gene expression. Evidence
reveals that microRNAs (miRNA) have been associated with OA, but little is known of their function in chondrocyte
ECM degradation. This study aimed to identify possible miRNAs that mediate IL-1b-induced down-regulation of
Sox9 as well as its known down-stream genes, collagen type II and aggrecan.
Methods: The miRNAs were predicted based on three classical databases. The expression levels of the predicted
miRNAs were assessed in IL-1b stimulated chondrocytes by real-time PCR. A luciferase reporter was used to test
the binding of the miRNAs to the 3’ untranslated regions (3’UTR) of Sox9. The predicted miRNAs were transfected
into chondrocytes to validate their relationship with Sox9. Functional analysis of the miRNAs on chondrocytes ECM
degradation was performed at both the mRNA and protein levels after miRNA transfection and IL-1b treatment.
Results: Six miRNAs were predicted to target Sox9, and their expression in IL-1b-stimulated chondrocytes was
revealed by real-time PCR. The luciferase reporter assay indicated that only miR-101 could bind to the 3’UTR of
Sox9. The expression of Sox9 was likewise negatively regulated by miR-101 in rat chondrocytes. Functional analysis
showed that miR-101 could aggravate chondrocyte ECM degradation, whereas miR-101 inhibition could reverse
IL-1b-induced ECM degradation.
Conclusion: miR-101 participates in IL-1b-induced chondrocyte ECM degradation. Down-regulating miR-101
expression can prevent the IL-1b-induced ECM degradation in chondrocytes. miR-101 probably functions by
directly targeting Sox9 mRNA.
Introduction
Articular cartilage is composed of a small number of
chondrocytes and a large amount of extracellular matrix
(ECM). Chondrocytes are the only cell types in cartilage
that function in the synthesis and catabolism of the ECM.
The ECM, which mainly consists of collagen type II and
aggrecan, maintains the structure of the cartilage as well
as the homeostasis in its extracellular environment [1].
During osteoarthritis (OA), the degeneration and insuffi-
cient synthesis of ECM cause the cartilage to malfunction
[1,2]. The inflammatory cytokine IL-1b has a key function
in the cartilage degradation during OA [3]. IL-1b stimu-
lates the synthesis of ECM-degrading enzymes, such as
collagenases and aggrecanase, thereby leading to break-
down of the chondrocyte ECM [4-6]. On the other hand,
IL-1b strongly inhibits the expression of cartilage-specific
genes, such as collagen type II and aggrecan, and causes
the insufficient synthesis of chondrocyte ECM [7,8]. In
this process, cartilage-specific gene expression is inhibited
via the down-regulation of Sox9, a transcription factor that
can directly promote the expression of collagen type II and
aggrecan [9-11]. The decreased Sox9 expression can lead
to down-regulation of collagen type II and aggrecan in the
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presence of inflammatory cytokines such as IL-1b [7] and
IL-6 [12]. The poor healing capacity of cartilage can be
caused by inhibited Sox9 expression [7]. Therapeutic stra-
tegies aim to develop biological agents that block these
two processes, thereby protecting chondrocytes from
inflammatory cytokine-induced ECM degradation.
miRNAs have attracted attention because of their crucial
roles in human disease and their potential as therapeutic
targets [13-15]. miRNAs are small noncoding RNAs that
can silence target mRNAs by binding to complementary
sequences in 3’ untranslated regions (3’UTR) to induce
target mRNA degradation or translational repression [16].
miRNAs have been associated with the collagenases and
aggrecanase that are stimulated by IL-1b in OA cartilage
degradation [17-19]. However, little is known about the
functions of miRNAs in IL-1b-induced down-regulation of
collagen type II and aggrecan genes in cartilage. Under-
standing these processes will provide new insights into a
therapeutic strategy to prevent cartilage damage.
We hypothesize that some miRNAs can participate in
chondrocyte ECM degradation by regulating Sox9 expres-
sion in the presence of IL-1b. In this study, we selected six
miRNAs from public miRNA databases; these miRNAs
were predicted to target the Sox9 gene and demonstrated
the direct targeting of Sox9 mRNA by miR-101. The func-
tional analysis demonstrated that miR-101 could aggravate
chondrocyte ECM degradation. The inhibition of miR-101
increased the expression of Sox9, collagen type II and
aggrecan, and could also prevent chondrocyte from IL-1b-
induced ECM degradation.
Materials and methods
Isolation of rat chondrocytes
Chondrocytes were isolated from the femoral condyle and
tibial plateau of Sprague-Dawley rats (150 g to 160 g). All
rats were obtained from Beijing Animal Administration
Center. Ethical approval was obtained from the Animal
Care and Use Committee of Peking University (number
LA2010-065). Rat articular cartilage was cut into small
fragments, followed by digestion first with 0.25% trypsin
(Invitrogen, Carlsbad, CA, USA) for 30 minutes and then
with 0.3% collagenase type II (Invitrogen) for 4 h at 37°C.
Then cells were suspended in DMEM (Invitrogen) with
10% fetal bovine serum (HyClone Laboratories, Losan,
UT, USA), 100 units/ml penicillin, and 100 units/ml strep-
tomycin. Chondrocytes were cultured at 37°C in a humidi-
fied atmosphere of 5% carbon dioxide and 95% air.
Primary chondrocytes at 80% confluence were used for all
the studies described here.
miRNA transfection and IL-Ib stimulation
A total of 2 × 105 chondrocytes in 2 ml DMEM were
incubated to 80% confluence in a 6-well plate and then
changed to serum-free DMEM for 12 h incubation. The
transfection of miRNA was performed according to the
manufacturer’s instruction. Briefly, 100 nM miRNA
mimic or 100 nM scrambled 22 nt nucleotides (miR-Scr,
with no homology to mammal genome) or 150 nM inhi-
bitors (designed and synthesized by RiboBio, Guangzhou,
China) were mixed with Lipofectamine 2000 (Invitrogen)
and then left at room temperature for 20 minutes. Before
the mixture was added, 1 ml fresh medium was added to
each well, and then the mixture was added for 12 h incu-
bation; 5 ng/ml IL-1b (PeproTech, Rocky Hill, NJ, USA)
or PBS was added to each well and incubated for an
appropriate period.
RNA isolation and real-time PCR analysis
Total RNA was extracted using TRIzol reagent (Invitro-
gen). Isolated RNA was reverse-transcribed with a com-
mercial kit (Promega, Madison, WI, USA), and real-time
PCR analysis was performed using the Mx3005 QPCR Sys-
tem (Agilent Technology, Palo Alto, CA, USA) with SYBR
Green PCR Master Mix (Toyobo, Osaka, Japan). The con-
ditions of real-time PCR were as follows: 95°C for 2 min-
utes, followed by 40 cycles of 95°C for 15 sec and 60°C for
30 sec. A dissociation stage was added at the end of the
amplification procedure. There was no nonspecific ampli-
fication determined by the dissolved curve. The PCR pri-
mers were as follows: Sox9 forward (FW), 5’-AGGAAGC
TGGCAGACCAGTA-3’ and reverse (RV), 5’- ACGAAG
GGTCTCTTCTCGCT-3’; Collagen type II FW, 5’-CACC
GCTAACGTCCAGATGAC-3’, and RV, 5’-GGAAGGCG
TGAGGTCTTCTGT-3’; Aggrecan FW, 5’-CCACTGGA-
GAGGACTGCGTAG-3’ and RV, 5’- GGTCTGTGCA
AGTGATTCGAG-3’; 18s RNA FW, ‘-GTAACCCGTT-
GAACCCCATT-3’, and RV, 5’-CCATCCAATCGGTAG-
TAGCG-3’.
For analysis of miR-101 expression, reverse transcription
and PCR were carried out using Bulge-Loop™ miRNA
qPCR Primer Set (RiboBio) according to the manufac-
turer’s instructions. The expression of Sox9, Collagen type
II, and Aggrecan relative to 18s RNA and the miRNA
expression relative to U6 (RiboBio) were determined using
the 2-ΔΔCT method [20].
Protein isolation and western blotting
Protein was extracted using lysis buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% NP- 40, and 0.1% sodium dode-
cyl sulfate), and the concentration was measured using the
BCA protein assay kit (Pierce, Rockford, IL, USA) using
bovine serum albumin as the standard. Proteins were run
on SDS-PAGE gels (10%) and electro-transferred to nitro-
cellulose membrane at 4°C for 2 h. The blots were probed
with anti-Sox9 (Millipore, Temecula, CA, USA) at 1:4000
dilutions overnight at 4°C, followed by incubation with
horseradish peroxidase-conjugated secondary antibody
(Santa Cruz, Santa Cruz, CA, USA, 1: 1000 dilutions) at
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room temperature for 1 h. Proteins were detected by che-
miluminescence according to the manufacturer’s recom-
mendations (ECL, Millipore). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an internal control.
Luciferase reporter construction, transfection, and dual
luciferase assay
The 3’ UTR of rat Sox9 gene [XM_001081628: GenBank]
was PCR-amplified from rat genomic DNA using primers
5’-CCGCTCGAGGGAGACCTTGAAGAGCAATGG-3’
and 5’-GAATGCGGCCGCCTTTCTCTCTTTCTCTCT
TTCTTTTTTTAAGG-3’, and cloned into the Xhol and
Notl sites of pmiR-RB-REPORT (Promega), which was
designated pmiR-Sox9-wt after sequencing. Site-directed
mutagenesis of the miR-101 target-site in the Sox9 3’UTR
was carried out using a site-directed mutagenesis kit
(Takara Shuzo, Kyoto, Japan), with pmiR-Sox9-wt as a
template. It was named pmiR-Sox9-mt (primers: FW, 5’-
CTTTTAGTATGTACTACGTATGACTCA-3’, RV, 5’-
GTAGTACATACTAAAAGTATTTAAAAT-3’).
HeLa cells were transfected with 300 ng of UTR reporter
(pMir-Report, Promega), 10 ng of control Renilla vector
(phRLTK, Promega), and 50 nM microRNA mimic with
1.5 μl Lipofectamine 2000 in each well of the 24-well
plates. Lysates were harvested 24 h after transfection, and
reporter activity was measured with Dual Luciferase Assay
(Promega).
Sulfated-glycosaminoglycan quantification
Cell suspension was analyzed for soluble sulfated-glyco-
saminoglycan (sGAG) secretion/formation by dimethyl-
methylene blue (DMMB) assay according to an
established protocol [21-23]; Briefly, 20 μl of cell suspen-
sion was mixed with 200 μl of DMMB reagent, and the
absorbance was measured at the 525 nm wavelength on
the FlexStation III (Molecular Devices, Sunnyvale, CA,
USA). A standard curve based on chondroitin 6-sulfate
from shark (Sigma, St. Louis, MO, USA) was established
to compare absorbance of the samples. Total sGAG were
normalized to total protein content in the cell lysate of
each group that was measured using the BCA protein
assay kit (Pierce).
Immunofluorescence analysis
Cultured cells were rinsed in PBS and fixed with 3.7% for-
maldehyde in PBS for 10 minutes at room temperature.
Goat serum was used to block nonspecific binding sites.
The cultured cells were then incubated with anti-Collagen
type II (Abcam, Cambridge, UK, 1:100 dilutions) in PBS
for 2 h at room temperature. After three PBS washes, each
for 5 minutes at room temperature, the cells were incu-
bated for 30 minutes with goat anti-rabbit IgG conjugated
to fluorescent cy5 dye (Abcam, 1:100 dilutions) in PBS.
After another round of three washes, the samples were
incubated with Hoechst 33342 for 5 minutes. After the
final round of three washes, samples were mounted and
observed under a confocal microscope (FV 1000 Olympus
IX-81, Olympus, Tokyo, Japan). Images were analyzed
using Image-Pro Plus 6.0 software (Media Cybernetics,
Silver Spring, MD, USA).
Construction of Sox9 plasmids and Sox9 knockdown by
small interfering RNA
Sox9 full-length vector and Sox9 CDS vector were pur-
chased from SinoGeneMax (Beijing, China). Small inter-
fering RNA (siRNA) against Sox9 (siSox9) and the
scrambled siRNA (siScr) were designed and synthesized by
RiboBio. The transfection of Sox9 full-length, Sox9 CDS
vector, siScr and siSox9 in chondrocytes was carried out
using Lipofectamine 2000 (Invitrogen) and performed
according to the manufacturer’s protocol.
Northern blot analysis
The northern blot analysis was performed with miRNA
Northern Blot Assay Kit (Signosis, Inc., Sunnyvale, CA)
following the manufacturer’s instructions. The oligonu-
cleotide probes used to detect miR-101 and U6 snRNA
are: miR-101, 5’- TTCAGTTATCACAGTACTGTA and
U6, 5’-AACGCTTCACGAATTTGCGT, as previously
reported [24]. U6 was used as an internal control.
Statistical analysis
In each experiment the samples were analyzed in tripli-
cate. Three independent experiments were performed,
each with different chondrocyte preparation. The statisti-
cal significance of the differences between groups were
calculated using analysis of variance (ANOVA). The
results from the same group were evaluated using Stu-
dent’s t-test. P-values less than 0.05 were considered statis-
tically significant. All data are presented as mean ± SD.
Results
miRNA prediction and expression of miRNA in IL-1b
treated chondrocytes
To investigate which miRNA might target Sox9, we first
searched three miRNA prediction databases: TargetScan
[25], miRbase [26] and DIANA-microT [27]. Six miRNAs
(miR-1, miR-101, miR-30b, miR-30c, miR-30d, and miR-
30e) were selected to potentially target Sox9 (Figure 1A).
Second, we used IL-1b-treated rat chondrocytes (at differ-
ent time points) as a screening platform to investigate
which miRNAs were correlated with IL-1b and Sox9 dur-
ing chondrocyte ECM degradation. A previous study has
shown that IL-1b markedly down-regulates Sox9 expres-
sion in chondrocytes [7]. Similarly, our result showed a
significant decrease in the Sox9 levels in rat chondrocytes
after IL-1b stimulation at both the mRNA and protein
levels (Figures 1B and 1C). Finally, these miRNAs were
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evaluated using real-time PCR to quantify the changes in
their expression after IL-1b treatment at 2, 4, and 6 h,
respectively. The expression of miR-101, miR-30b, miR-
30c, miR-30d and miR-27b was detected (Figure 1D) but
miR-1 and miR-30e expression was not (data not shown).
miR-27b was used as a positive control as previously
reported [19]. The increasing expression of miR-101, miR-
30b, miR-30c, and miR-30d emerged at different time
points after IL-1b treatment (Figure 1D). These results sug-
gested a correlation between the increased expression levels
of miR-101, miR-30b, miR-30c, and miR-30d, as well as the
decreased Sox9 expression level. To determine whether the
in silico analysis predicted the miRNA-targeting of Sox9
mRNA in a cellular environment, we performed luciferase
assays and examined the changes in the Sox9 levels after
miRNA transfection.
Figure 1 microRNA prediction and its expression in IL-1b-treated chondrocytes. (A) Six microRNAs were selected to target Sox9 using
three classic prediction databases. Primary rat chondrocytes were treated with IL-1b (5 ng/ml) for 2, 4 and 6 h. Sox9 expression was analyzed by
real-time PCR and western blot. (B and C) Sox9 expression was markedly decreased at the mRNA and protein levels with the increasing duration
of IL-1b stimulation. The upper panels (C) are representative images of the western blot analysis. The lower panels are densitometric analyses
performed with images of three independent experiments, respectively; n = 3,*P < 0.05 versus 0 h. (D) microRNAs expression in IL-1b-induced
chondrocytes was analyzed by real-time PCR; n = 3,*P < 0.05 versus 0 h.
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Analysis and verification of miRNA target sites
The miR-Report luciferase reporter was constructed to
determine whether miRNAs could directly target the 3’
UTR of Sox9 (Figure 2A). The reporter was co-transfected
with miRNA mimics. A scrambled 22 nt mimic, miR-Scr,
(with no homology to the mammal genome) was used as a
control. Reporter activity was not affected by the scrambled
mimic (miR-Scr). The miR-101 mimic significantly reduced
the luciferase activity in the wild-type Sox9 3’UTR reporter
but not in the mutant reporter (Figure 2C). Further analy-
sis indicated that the Sox9 3’UTR contained the miR-101
target site, and these binding regions were conserved in dif-
ferent species (Figure 2B). However, luciferase activity was
not reduced with the mimics of miR-30b, miR-30c, and
miR-30d (Figure 2C). To verify Sox9 a target of miR-101 in
primary chondrocytes, chondrocytes were transfected with
the miRNA mimic and miRNA inhibitor. miR-Scr was
used as a negative control. Sox9 expression was evaluated
by real-time PCR and western blot analysis. miR-101
repressed the Sox9 expression, whereas the inhibition of
miR-101 increased the Sox9 expression at both mRNA and
protein levels in rat chondrocytes (Figures 2D and 2E).
However, no negative regulatory effects on Sox9 expression
were observed in miR-30b, miR-30c and miR-30d on
(Figures 2D and 2E). Combined with the luciferase assay
results, we proposed that only miR-101 directly targets
Sox9, thereby negatively regulating Sox9 expression.
Recently, miR-145 has been described to target Sox9 in
Figure 2 Validation of the targeting effect of microRNAs on Sox9. (A) The diagram illustrates the construction of Sox9 3’ UTR luciferase
reporter. (B) The conserved sequences of miR-101 and the 3’UTRs of Sox9 in different species are compared. The underlined sequences indicate
a sequence complementary in miR-101 to a specific binding site within the 3’UTR of Sox9. The sequences in the frame were used in our study.
(C) Luciferase activity of the Sox9 3’UTR reporter was analyzed in HeLa cells. miRNAs were co-transfected with the wild-type Sox9 3’ UTR or
mutant vector. Scrambled 22 nt mimic (miR-Scr) was used as a negative control; n = 3,*P < 0.05 versus miR-Scr group. MT refers to mutant Sox9
3’UTR reporter. Primary rat chondrocytes were transfected with the miRNA mimic and miRNA inhibitor. miR-Scr was used as a negative control.
Sox9 expression was analyzed by real-time PCR and western blot 24 h post miRNA transfection (D and E). Lower panels (E) show the
densitometric analysis of Sox9 expression (upper panels), which is normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The
analysis was performed using images from three independent experiments; n = 3,*P < 0.05 versus miR-Scr group.
Dai et al. Arthritis Research & Therapy 2012, 14:R268
http://arthritis-research.com/content/14/6/R268
Page 5 of 11
chondrocytes [28,29]. By assessing the miR-145 expression
in the presence of IL-1b, there was no significant increased
miR-145 level observed, and no time- or concentration-
dependent manner in our experimental system (Figure S1
in Additional file 1). Furthermore, we examined miR-101
and Sox9 expression level at different concentrations of
IL-1b. We found that the increasing miR-101 expression
had an IL-1b concentration-dependent effect on chondro-
cytes at 6 h and was correlated with Sox9 expression
(Figure S2 in Additional file 1). These further validate the
abovementioned finding that miR-101 directly targets Sox9.
All subsequent work was then focused on miR-101.
Effects of miR-101 on IL-1b-induced ECM degradation
To further analyze the effect of miR-101 on IL-1b-induced
ECM degradation, the chondrocytes were transfected with
miR-Scr, miR-101 mimic (mimic), or miR-101 inhibitor
(inhibitor with a complementary sequence of miR-101).
The cells were then treated with or without IL-1b 12 h
post-miRNA transfection. The average miR-101 expres-
sion level post-miR-101 mimic transfection reached
300-fold that of the miR-Scr group. However, the average
miR-101 level was 0.56-fold that of the miR-Scr group
(Figure S3A in Additional file 1). The chondrocytes exhib-
ited an elongated fibroblast-like morphology and decrea-
sed cell density in response to IL-1b treatment (Figure S4
in Additional file 1). Interestingly, the morphological
changes and decreased cell density of the chondrocytes
were likewise seen after miR-101 mimic transfection,
regardless of whether they were treated with IL-1b or not
(Figure S4 in Additional file 1). By contrast, chondrocytes
maintained their spherical shape after transfection of the
miR-101 inhibitor. The cell density was not significantly
decreased, regardless of IL-1b treatment (Figure S4 in
Additional file 1).
Collagen type II and aggrecan are chondrocyte ECM
genes that are down-regulated during chondrocyte ECM
degradation [12,30,31]. In the present study, IL-1b inhibited
the expression of collagen type II and aggrecan (Figure 3A
and 3B, respectively). Similarly, the expression of collagen
type II and aggrecan decreased after miR-101 transfection
(Figure 3A and 3B, respectively). However, the expression
of these two genes increased after miR-101 inhibitor trans-
fection, regardless IL-1b treatment (Figure 3A and 3B,
respectively). This result indicates that silencing miR-101 in
chondrocytes can reverse the IL-1b-induced down-regu-
lated expression of collagen type II and aggrecan. However,
inhibiting miR-101 expression also increased collagen type
II in the untreated chondrocytes (Figure 3A), indicating
that the untreated chondrocytes have already expressed
miR-101. Indeed, real-time PCR and northern blot analysis
confirmed that the untreated chondrocytes expressed miR-
101 (Figure S3B and S3C in Additional file 1). The level of
miR-101 was lower than that of huh7 cells but higher than
that of HeLa cells; both cell lines have been documented to
have the basal miR-101 expression [32].
To assess the content changes of chondrocyte ECM, the
secreted collagen type II content was evaluated by immu-
nofluorescence staining. The DMMB assay was used to
evaluate the concentration of sulfated-glycosaminoglycan
(sGAG), a main form of aggrecan secreted by chondro-
cytes in cartilage. Similar to the abovementioned mRNA
changes, the collagen type II and sGAG concentrations
decreased after IL-1b simulation (Figures 3C, 3D and 3E).
Overexpression of miR-101 decreased collagen type II and
sGAG concentrations, regardless of IL-1b treatment (Fig-
ures 3C, 3D and 3E). However, silencing of miR-101 main-
tained collagen type II and sGAG content, which inhibited
the effects of IL-1b (Figures 3C, 3D and 3E).
These results suggested that miR-101 mediate IL-1b-
induced down-regulation of collagen type II and aggrecan,
thereby affecting the changing concertrations of collagen
type II and sGAG. Based on previous studies [7,9-11],
Sox9 can directly promote the expression of collagen type
II and aggrecan, whereas decreased Sox9 expression can
down-regulate these two genes in the presence of IL-1b.
Based on the combined results, mediation of these effects
by miR-101 via Sox9 regulation should be investigated.
miR-101 mediate IL-1b-induced down-regulation of
collagen type II and aggrecan, probably by targeting Sox9
We have shown that overexpression of miR-101 decreases
the level of ECM gene expression as well as synthesis of
collagen type II and aggrecan. Furthermore, silencing
miR-101 inhibits these effects. Whether Sox9 participates
in these processes remains unknown. Thus, Sox9 expres-
sion at both mRNA and protein levels was first assessed in
the abovementioned treated chondrocytes. The results
showed that IL-1b reduced Sox9 expression at both the
mRNA and protein levels (Figure 4A and 4B). Further-
more, overexpression of miR-101 reduced Sox9 expres-
sion, whereas silencing of miR-101 increased Sox9
expression, whether the cells were treated with IL-1b or
not (Figure 4A and 4B). Expression of Sox9 paralleled the
expression of collagen type II and aggrecan. In addition,
silencing miR-101 expression could reverse the down-
regulation of Sox9 that was caused by IL-1b (Figure 4A
and 4B). These results indicated that Sox9 participates in
the miR-101 function during IL-1b-induced chondrocyte
ECM degradation. To confirm if the effects of miR-101
were achieved by regulating Sox9, firstly, chondrocytes
were co-transfected with miR-101 mimic or miR-Scr
together with Sox9 vector with (Sox9 full length) or without
(Sox9 CDS) the 3’UTR sequence. The expression of Sox9
was reduced in the chondrocytes that were co-transfected
with miR-101 mimic and Sox9 full-length vector. The effect
of miR-101 was partly reversed in the chondrocytes
co-transfected with Sox9 CDS vector without 3’UTR for
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miR-101 binding (Figure 4C and 4D). Secondly, chondro-
cytes were first transfected with the miR-101 inhibitor and
then transfected with siSox9, miR-Scr and siScr were used
as negative controls. The expression of Sox9 was
significantly reduced by siSox9, and the increased Sox9
level post miR-101 inhibitor transfection was reduced by
co-transfection with siSox9 (Figure 4E). Moreover, an
increase in sGAG content was observed after transfection
Figure 3 Effects of miR-101 on IL-1b-induced chondrocyte extracellular matrix (ECM) degradation. Primary rat chondrocytes were
transfected with miR-Scr, miR-101 mimic, and miR-101 inhibitor, and then treated with or without IL-1b 12 h post-miRNA transfection. (A and B)
The expression of collagen type II (A) and aggrecan (B) was evaluated by real-time PCR after transfection of miR-101 mimic or inhibitor with or
without IL-1b treatment; n = 3, *P < 0.05. (C) The collagen type II expression of transfected chondrocytes was assessed by immunofluorescence
staining method. Original magnification: × 60. Bars = 50 μm. (D) The fluorescence intensity of the images (C) was analyzed using Image-Pro Plus
6.0 software. Data are expressed as the average of at least five images; n = 3, *P < 0.05. (E) The sGAG content in the cell suspension was
assessed by dimethylmethylene blue (DMMB) assay after transfection of miR-101 mimic or inhibitor with or without IL-1b treatment. Data were
normalized by total protein content of the cell lysate in each group; n = 3, *P < 0.05.
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Figure 4 miR-101 function during IL-1b-induced chondrocyte extracellular matrix (ECM) degradation probably occurs through
regulation of Sox9. Primary rat chondrocytes were transfected with miR-Scr, miR-101 mimic, and miR-101 inhibitor, and then treated with or
without IL-1b 12 h post-miRNA transfection in the same manner as mentioned above. (A and B) Sox9 expression was analyzed by real-time PCR
(A) and western blot (B) 24 h post miRNA mimic, inhibitor, or miR-Scr transfection. The right panel (B) is the densitometric analysis of Sox9
expression (left panel), normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The analysis was performed using images of three
independent experiments, respectively; n = 3, *P < 0.05. (C and D) Primary rat chondrocytes were co-transfected with miR-Scr or miR-101 mimic
together with Sox9 full-length vector (Sox9 expression vector containing both UTR and CDS regions) or Sox9 CDS vector (Sox9 expression vector
containing only CDS region, no UTR). Sox9 expression was analyzed by real-time PCR (C) and western blot (D) 24 h post transfection; n = 3,*P <
0.05. (E and F) Primary rat chondrocytes were first transfected with miR-Scr or miR-101 inhibitor, and then siRNA against Sox9 (siSox9) or
scrambled siRNA (siScr) were transfected. Sox9 expression was analyzed by western blot (E) 24 h post transfection. The lower panel (E) is the
densitometric analysis of Sox9 expression (upper panel), normalized by GAPDH. The analysis was performed using images of three independent
experiments, respectively; n = 3,*P < 0.05. (F) The sGAG content in the cell suspension was assessed by dimethylmethylene blue (DMMB) assay.
Data were normalized by total protein content in the cell lysate in each group; n = 3,*P < 0.05.
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with the miR-101 inhibitor alone; however, there was a
remarkable decrease in sGAG content after co-transfection
with miR-101 inhibitor and siSox9 (Figure 4F), thereby sug-
gesting that Sox9 might be a functional mediator of
the miR-101-mediated changes in sGAG concentration.
Combined with the abovementioned results, the miR-101-
mediate IL-1b-induced down-regulation of collagen type II
and aggrecan was probably achieved by regulating its target
gene Sox9.
Discussion
The degradation of cartilage in OA is characterized by
two phases: a degradative and a biosynthetic phase
[2,33,34]. In the degradative phase, the enzymes, a disin-
tegrin and metalloproteinase with thrombospondin
motifs (ADAMTS) and matrix metalloproteinases
(MMPs), produced by chondrocytes digest the ECM in
the presence of inflammatory cytokines; matrix synthesis
is likewise inhibited by inflammatory factors through the
down-regulation of ECM genes. In the biosynthetic
phase, the chondrocytes, which are the only cell types in
cartilage, attempt to repair the damaged ECM. However,
these cells cannot synthesize enough ECM because of the
low level of ECM gene expression. Consequently, the
erosion of the cartilage is accelerated. Evidence has
revealed that miRNAs are associated with the expression
of ECM degradation enzymes in the presence of IL-1b.
Miyaki, et al. [17] reported that miR-140 could down-
regulate ADAMTS-5 expression in IL-1b-induced OA
chondrocytes. Tardif, et al. [18] and Akhtar, et al. [19]
demonstrated that miR-27b inhibits the expression of
MMP-13 in IL-1b-induced OA chondrocytes. However,
to date, evidence of miRNAs participation during the
down-regulation of ECM genes in the presence of IL-1b
has not been well documented.
In the current study, we provide a new insight on the
miRNAs that are involved in IL-1b-induced chondrocyte
ECM degradation. We demonstrate that miR-101 mediate
IL-1b-induced down-regulation of Sox9, and its known
down-stream genes collagen type II and aggrecan; how-
ever, silencing miR-101 can reverse the IL-1b-induced
down-regulation of these two genes as well as the degrada-
tion of the ECM proteins, collagen type II and sGAG.
Thus, miR-101 may serve as a new target for preventing
the IL-1b-induced chondrocyte ECM degradation.
The effect of miR-101 on the IL-1b-induced chondro-
cyte ECM degradation is probably achieved through Sox9
regulation. The following evidence support this hypothesis:
First, the expression of miR-101 is negatively correlated
with Sox9 expression, and the decreased Sox9 expression
is due to the overexpression of miR-101 by targeting its
3’UTR. Second, Sox9 is a target of miR-101, and can
directly promote ECM gene expression and ECM synth-
esis [9-11]. The decreased Sox9 expression can lead to the
down-regulation of collagen type II and aggrecan in the
presence of inflammatory cytokines [12]. Third, the
increased content of sGAG caused by silencing miR-101
expression was significantly decreased by co-transfection
with siSox9. However, miR-101 has no effects on the other
aspects of Sox9 regulation, such as p38. It has been
reported that p38 can regulate Sox9 [35], but miR-101 did
not affect the p38 level (Figure S5C in Additional file 1),
suggesting that the effect of miR-101 on Sox9 may be
mainly through the direct targeting.
We also found that miR-101 could be induced by IL-1b,
which is a direct effect demonstrated as a concentration-
dependent effect on the endogenous miR-101 level (Figure
S2A, S2B and S2C in Additional file 1). The regulation of
IL-1b on miR-101 is at transcriptional level, because IL-1b
can lead to an increased level of pre-miR-101 (Figure S3D
in Additional file 1). However, miR-101 has no influence on
the classic components of IL-1b pathway such as total NF-
kB and the nuclear translocation of nuclear factor (NF)-kB
(Figure S5D and S5E in Additional file 1).
Inhibiting miR-101 expression notably resulted in
increased collagen type II synthesis in untreated chondro-
cytes. This phenomenon may indicate that chondrocytes
have already expressed miR-101. Thus, we examined the
basal levels of miR-101 in primary chondrocytes. As
expected, we found that untreated chondrocytes had
already expressed miR-101 (Figure S3B and S3C in Addi-
tional file 1).
miR-145 has been reported to target Sox9 in chondro-
cytes [28,29]. However, in the current study, we did not
observe a negative correlation between the expression of
miR-145 and Sox9 in the presence of IL-1b. The IL-1b
treatment did not have any time- or concentration-depen-
dent effects on miR-145 (Figure S1A and S1B in Additional
file 1). Therefore, our work focused on miR-101.
However, it was noted that expression of Sox9 continued
to decline with increasing duration of IL-1b treatment.
The expression levels of miR-101 exhibited a decrease at
4 h and 6 h of IL-1b treatment compared to the levels at
2 h, although miR-101 expression remained higher than at
0 h. This finding may indicate that the reduced Sox9 level
was not completely regulated by miR-101. Furthermore,
miR-101 may have other targets in these processes.
Further research is necessary to obtain additional informa-
tion on miR-101 function.
miR-101 has been associated with cancer [24,36,37]
and immune response [38]. Our findings provide evi-
dence that miR-101 might participate in inflammation
and cause chondrocyte ECM degradation.
Conclusions
miR-101 is involved in IL-1b-induced down-regulation
of collagen type II and aggrecan, and its inhibition can
prevent IL-1b-induced chondrocyte ECM degradation.
Dai et al. Arthritis Research & Therapy 2012, 14:R268
http://arthritis-research.com/content/14/6/R268
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This miRNA probably function through its target gene
Sox9.
Additional material
Additional file 1: Supplemental figures and figure legends. This file
contains 5 figures (Figure S1-S5) and their figure legends. Figure S1:
Relative miR-145 expression levels at present of IL-1b in primary rat
chondrocytes. Figure S2: miR-101 has an IL-1b concentration dependent
effect in primary chondrocyte. Figure S3: miR-101 and the pri-miR-101
expression level. Figure S4: Morphological changes of the chondrocytes
post miRNA transfection and IL-1b treatment. Figure S5: Effect of miR-101
transfection on the components of IL-1b signaling.
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